TrialCompass™ TCL
Back to results
Phase 1RecruitingPriority 3 · Moderate priorityNCT07465835

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is comparing ELA026 against other options for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 4 US locations.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

ELA026 (DRUG): Weekly maintenance dosing via subcutaneous injection

Drugs / treatments
ELA026
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

NCT07465835

Phase: Phase 1 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 1 trial is comparing ELA026 against other options for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 4 US locations.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • May require specific number of prior treatments

What's being tested

ELA026 (DRUG): Weekly maintenance dosing via subcutaneous injection

Drugs / treatments: ELA026

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 84 patients

Primary endpoint: DLTs and treatment emergent adverse events (TEAEs), including serious adverse advents (SAEs)

Ages: 18 Years to —

Start date: 2026-02-17 | Est. completion: 2028-12

Locations

4 US sites · 4 total

Connecticut, Georgia, Michigan, Ohio

Contact

Clinical Trials Electra Clinical Trials Information | clinicaltrials@electra-therapeutics.com | Please email

Sponsor: Electra Therapeutics Inc. (INDUSTRY)

Tags

CTCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07465835

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.